Evidence map›Paper›PMID 26607774›Full record

ArticleThe Journal of molecular diagnostics : JMD2016

High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer.

Yu Wu, Jamie R Schoenborn, Colm Morrissey, Jing Xia, Sandy Larson, Lisha G Brown, Xiaoyu Qu, Paul H Lange, Peter S Nelson, Robert L Vessella and 1 more

Abstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu WuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jamie R SchoenbornClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, Washington.
Jing XiaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Sandy LarsonDepartment of Urology, University of Washington, Seattle, Washington.
Lisha G BrownDepartment of Urology, Puget Sound VA Health Care System, Seattle, Washington.
Xiaoyu QuClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Paul H LangeDepartment of Urology, University of Washington, Seattle, Washington.
Peter S NelsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Urology, University of Washington, Seattle, Washington.
Robert L VessellaDepartment of Urology, University of Washington, Seattle, Washington; Department of Urology, Puget Sound VA Health Care System, Seattle, Washington.
Min FangClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Urology, University of Washington, Seattle, Washington. Electronic address: mfang@fhcrc.org.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Steven P. Balk · 2013 to 2026
$25.0M
Transmembrane Proteases and Prostate CarcinogenesisP01CA085859 · NCI · UNIVERSITY OF WASHINGTON · PI VESSELLA, ROBERT LOUIS · 2002 to 2013
$21.2M
NCI NIH HHS P01 CA085859NCI NIH HHS P01CA085859NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA097186NCI NIH HHS P50CA97186
6 · The paper itself

Abstract

Circulating tumor cells and disseminated tumor cells (DTCs) are of great interest because they provide a minimally invasive window for assessing aspects of cancer biology, including tumor heterogeneity, a means to discover biomarkers of disease behavior, and a way to identify and prioritize therapeutic targets in the emerging era of precision oncology. However, the rarity of circulating tumor cells and DTCs poses a substantial challenge to the consistent success in analyzing their molecular features, including genomic aberrations. Herein, we describe optimized and robust methods to reproducibly detect genomic copy number alterations in samples of 2 to 40 cells after whole-genome amplification with the use of a high-resolution single-nuclear polymorphism-array platform and refined computational algorithms. We have determined the limit of detection for heterogeneity within a sample as 50% and also demonstrated success in analyzing single cells. We validated the genes in genomic regions that are frequently amplified or deleted by real-time quantitative PCR and nCounter copy number quantification. We further applied these methods to DTCs isolated from individuals with advanced prostate cancer to confirm their highly aberrant nature. We compared copy number alterations of DTCs with matched metastatic tumors isolated from the same individual to gain biological insight. These developments provide high-resolution genomic profiling of single and rare cell populations and should be applicable to a wide-range of sample sources.

Indexed as

AgedAlgorithmsBiomarkers, TumorBone NeoplasmsCell Line, TumorComparative Genomic HybridizationDNA Copy Number VariationsGene DosageGene Expression ProfilingHumansLimit of DetectionLiver NeoplasmsLymphatic MetastasisMaleNeoplastic Cells, CirculatingOligonucleotide Array Sequence AnalysisBiomarkers, Tumor

Identifiers

PMID26607774
PMCPMC4715223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.